Cyclosporine-based immunosuppressive strategies for kidney recipients: Interim analysis of German data from the Multinational Observational Study (MOST)

Transplantation Proceedings

Volumn 37, Issue 3, 2005, Pages 1597-1600

  Kliem, V ^a   Fritsche, L ^b   Haller, H ^c   Suwelack, B ^d   Abendroth, D ^e   Fornara, P ^f   Pietruck, F ^g   Frei, U ^b   Donauer, J ^h   Lison, A E ⁱ   Michel, U ^j   Ulbricht, B ^j  

^a Nephrological Center Niedersachsen   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e UNIVERSITY OF ULM   (Germany)

^f MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ Central Hospital   (Germany)

^j NOVARTIS PHARMA GMBH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOKINE RECEPTOR ANTAGONIST; INTERLEUKIN 2 RECEPTOR BLOCKING AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; UNCLASSIFIED DRUG;

ADULT; CONFERENCE PAPER; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; GERMANY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFORMATION PROCESSING; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECIPIENT; TREATMENT OUTCOME;

ADULT; ANTILYMPHOCYTE SERUM; CYCLOSPORINE; DRUG THERAPY, COMBINATION; GERMANY; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MUROMONAB-CD3; PATIENT SELECTION; POSTOPERATIVE COMPLICATIONS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 21044455591     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.09.017     Document Type: Conference Paper

References (9)

1. G. Opelz, B. Dohler Cyclosporine and long-term kidney graft survival Transplantation 72 2001 1267
2. W.S. Cherikh, H.M. Kauffman, J. Maghirang A comparison of discharge immunosuppressive drug regimens in primary cadaveric kidney transplantation Transplantation 76 2003 463
3. S.B. Campbell, E. Hothersall, J. Preston Frequency and severity of acute rejection in live- versus cadaveric-donor renal transplants Transplantation 76 2003 1452
4. M. Salvadori, A. Rosati, A. Bock One-year posttransplant renal function is a strong predictor of long-term kidney function: results from the Neoral-MOST observational study Transplant Proc 35 2003 2863
5. J.H. Helderman, W.M. Bennett, D.M. Cibrik Immunosuppression: practice and trends Am J Transplant 3 Suppl 4 2003 41
6. D. Adu, P. Cockwell, N.J. Ives Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials BMJ 326 2003 789
7. A.C. Webster, E.G. Playford, G. Higgins Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials Transplantation 77 2004 166
8. P. Keown, R. Balshaw, S. Khorasheh Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation BioDrugs 17 2003 271
9. A.M. Wiland, J.C. Fink, M.R. Weir Should living unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial Transplantation 77 2004 422